[
    {
      "name": "BE-X5",
      "identifiers": [
        { "type": "nct", "identifier": "NCT75521706" }
      ],
      "status": "Planning",
      "title": "Effect of combination of device Megabond with varying doeses of Amoxocillin Treatment of Patients With Advanced Malignancies",
      "phase": "III",
      "interventions": [
        { "type": "device", "name": "Megabond 5000" },
        { "type": "drug", "name": "Amoxocillin" }
      ],
      "therapeutic-area": "Oncology",
      "current-protocol": "v1",
      "protocol-amendments": [
        { "version": "v1", "date": "04-MAR-2024", "description": "initial protocol" }
      ]
    },
    {
      "name": "MK-3475-028",
      "identifiers": [
        { "type": "nct", "identifier": "NCT03421378" }
      ],
      "status": "Active",
      "title": "An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Advanced Malignancies",
      "phase": "II",
      "interventions": [
        { "type": "drug", "name": "INM-176" }
      ],
      "therapeutic-area": "Oncology",
      "current-protocol": "v2",
      "protocol-amendments": [
        { "version": "v1","date": "01-MAY-2023","description": "initial protocol" },
        { "version": "v2","date": "24-NOV-2023","description": "updated protocol" }
      ]
    },
    {
      "name": "XL-184-001",
      "identifiers": [
        { "type": "nct", "identifier": "NCT44429081" }
      ],
      "status": "Active",
      "title": "Effect of Different Doses of SAR110894 on Growths in Patients With Mild to Moderate Cancerous Tumors",
      "phase": "III",
      "interventions": [
        { "type": "drug", "name": "SAR110894" }
      ],
      "therapeutic-area": "Oncology",
      "current-protocol": "v1",
      "protocol-amendments": [
        { "version": "v1", "date": "01-MAY-2023", "description": "initial protocol" }
      ]
    },
    {
      "name": "AN-PARAB-001",
      "identifiers": [
        { "type": "nct", "identifier": "NCT86177491" }
      ],
      "status": "Complete",
      "title": "Short-term Effects on Cervical Cancerous Tumors in Patients On the Drug Fallaxin",
      "phase": "III",
      "interventions": [
        { "type": "drug","name": "Fallaxin" }
      ],
      "therapeutic-area": "Hematology",
      "current-protocol": "v1",
      "protocol-amendments": [
        { "version": "v1","date": "01-MAY-2023","description": "initial protocol" }
      ]
    }
  ]